Thyrocare Technologies Limited has informed the Exchange regarding changes in Senior Managerial Personnel of the Company.
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 12.1 pts more than Nifty Microcap 250 and 11.0 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Thyrocare's board approved Q1 FY26 (ended June 30, 2025) unaudited results showing strong year-on-year growth: consolidated revenue rose to Rs. 193.03 crores (vs Rs. 156.91 crores in Q1 FY25), with net profit jumping to Rs. 38.29 crores (vs Rs. 23.94 crores). Standalone revenue grew to Rs. 178.89 crores and profit to Rs. 36.05 crores. CFO Mr. Alok Kumar Jagnani stepped down to take up the Group CFO role at parent API Holdings and will join Thyrocare's board as a Non-Executive Director. Mr. Vikram Gupta (ex-Rebel Foods, Tata Play Fiber, Vodafone Idea) has been appointed as the new CFO. Non-Executive Director Mr. Hardik Kishor Dedhia also resigned citing pre-occupation, and VP Franchisee Operations Mr. Amit Bhola resigned effective July 31, 2025.
Strong Q1 results with ~23% YoY revenue growth and ~60% YoY profit growth at the consolidated level are positive for shareholders. The CFO transition is orderly — Jagnani moves to the parent group and stays on Thyrocare's board, while a seasoned finance professional takes over, suggesting continuity rather than disruption.